Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesInfectious DiseaseAetna travel vaccine Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0473

    Vaccines for Travel

    Customize your policy alerts

    Sign up for Aetna Policy 0473 alerts

    Get alerted when Policy 0473 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, coverage limitations, and coding for vaccines commonly considered for international travel; applies to providers submitting claims for Aetna members seeking travel-related immunizations.

    Policy Summary
    PayerAetna
    PolicyVaccines for Travel
    Policy CodePolicy 0473
    Change TypeNo material change
    Effective DateApr 13, 2001
    Last ReviewFeb 1, 2024
    Next Review DateMay 9, 2024
    Key ActionConfirm member plan benefits for travel vaccine coverage and submit appropriate CPT/HCPCS and ICD-10 codes.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    >30vaccine-specific CPT/HCPCS codes listed
    Z23ICD-10 code listed
    Most Aetna HMO plansplans may exclude travel vaccines
    Some vaccines experimentalsome vaccines investigational
    FDA-approved (2023)chikungunya vaccine approval
    ErveboEbola (Ervebo) approved

    Coverage Criteria for Travel Vaccines

    General medical necessity criteria

    Covered when ALL of the following are met for each vaccine:

    General coverage logic: Vaccine is considered medically necessary when the specific vaccine's indications (e.g., travel to an endemic area or documented high-risk exposure) and the policy's standard administration schedule are met, and the member's benefit plan includes coverage for preventive/travel vaccines.

    See vaccine-specific entries in policy for age limits, contraindications, and timing.

    Experimental / Investigational

    Not covered (considered experimental/investigational):

    Experimental vaccines: Malaria vaccines for travel (no effective malaria vaccine developed) and oral or skin-patch cholera vaccines for prevention of entero-toxigenic Escherichia coli (ETEC) diarrhea are considered experimental/investigational and not medically necessary.

    Clinical value has not been established per policy background (Cochrane reviews and trial evidence).

    Policy Summary
    PayerAetna
    PolicyVaccines for Travel
    Policy CodePolicy 0473
    Change TypeNo material change
    Effective DateApr 13, 2001
    Last ReviewFeb 1, 2024
    Next Review DateMay 9, 2024
    Key ActionConfirm member plan benefits for travel vaccine coverage and submit appropriate CPT/HCPCS and ICD-10 codes.
    SourceLink
    On This Page
    Coverage Criteria for Travel VaccinesBilling Codes and Coding GuidanceProvider Actions, Documentation, and AuthorizationBackground and ContextDefinitions and Key TermsRevision History

    Vaccine-specific coverage considerations (informational)

    Key vaccine-specific indications and considerations referenced:

    Chikungunya vaccine (Ixchiq): Indicated for prevention of chikungunya disease in individuals 18 years of age and older who are at increased risk of exposure; administered as a single intramuscular dose; contraindicated in immunocompromised individuals and those with severe allergy to components; vaccine viremia typically occurs in the first week and resolves by 14 days.age >= 18 years and increased exposure risk

    Approval under accelerated pathway based on immunogenicity; continued approval may require confirmatory studies.

    ACIP draft considerations for chikungunya: Draft ACIP recommendations propose vaccination for adults traveling to areas with outbreaks or transmission within the last 5 years, and consideration for older persons or those with extended stays or greater exposure (e.g., cumulative ~2+ weeks).travel to outbreak area or evidence of recent transmission; older age or prolonged exposure

    ACIP deliberations noted (anticipated vote Feb 2024).

    Tick-borne encephalitis vaccine (Ticovac): FDA-approved for active immunization to prevent tick-borne encephalitis in individuals 1 year of age and older; primary series (three doses) produces high seropositivity and boosters/ schedules per product labeling; clinical trials and real-world data demonstrate high effectiveness.age >= 1 year

    Three-dose primary series; better immunogenicity when started younger than age 50 in trials.

    Measles (MMR) for travelers: Infants 6–11 months should receive 1 MMR dose before departure; children 12 months and older should receive 2 doses separated by at least 28 days; adults without evidence of immunity should receive 2 doses; live measles-containing vaccine is contraindicated in pregnancy and in persons with severe immunodeficiency.infant pre-travel dosing and adult immunity gaps

    Infants vaccinated before 12 months still require routine doses at 12–15 months and again at least 28 days later.

    Travelers' diarrhea and cholera-related vaccines (Dukoral/ETEC): Available RCT evidence does not support routine use of Dukoral or other ETEC-specific vaccines for broad prevention of travelers' diarrhea; some trials showed limited or no statistically significant protection and possible adverse effects (e.g., vomiting).insufficient evidence for routine use

    Counsel travelers on self-treatment and preventive measures rather than routine vaccination.

    Travel vaccine clinical guidance and evidence

    Informational coverage stance and recommended use per ACIP and trial evidence

    Ervebo indication: Pre-exposure vaccination with Ervebo (rVSVΔG-ZEBOV-GP) is indicated for prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older who are at potential risk of exposure (outbreak responders, BSL‑4 laboratorians, and healthcare personnel at designated Ebola Treatment Centers).age >= 18 years

    ACIP recommended pre-exposure vaccination for at-risk adults; vaccine is FDA-approved.

    Ervebo limitations: Duration of protection is unknown; Ervebo does not protect against other species of Ebolavirus or Marburgvirus; effectiveness when given concurrently with antivirals, immune globulin, or blood/plasma transfusions is unknown.

    Counsel patients on limitations and continue infection-control measures.

    Ervebo safety considerations: Label includes warnings for anaphylaxis; common adverse events include injection-site pain, swelling, redness and systemic events such as headache, feverishness, myalgia, fatigue, arthralgia, nausea and arthritis; vaccine virus RNA has been detected in bodily fluids post-vaccination and theoretical transmission is possible.

    Monitor for adverse events and advise patients accordingly.

    Pregnancy and travel vaccines summary: Influenza and Tdap are supported for use in pregnancy; observational or trial data support meningococcal, hepatitis A, hepatitis B, rabies and yellow fever in pregnancy in some circumstances; limited data exist for polio, typhoid, Japanese encephalitis, tick-borne encephalitis and MMR — risk‑benefit counseling recommended for pregnant travelers.

    Live vaccines generally contraindicated in pregnancy; individual risk assessment required.

    Yellow fever vaccine in immunocompromised individuals: Systematic review/meta-analysis found a pooled proportion of adverse events of approximately 8.5% in immunocompromised individuals with substantial bias across studies and a pooled risk ratio of 1.00 (95% CI 0.78–1.29) in cohort studies, indicating that individual risk assessment is warranted when considering yellow fever vaccination in immunocompromised travelers.

    Consider individual etiology of immunosuppression and travel risk when deciding vaccination.

    Coverage for vaccines administered for travel is plan-dependent. Most Aetna HMO plans exclude coverage of vaccines for travel; coverage for medically necessary travel vaccines may be available in traditional plans that include preventive benefits. Providers should verify the member's benefit plan before billing or administering travel-related vaccines.

    Live, attenuated vaccines are contraindicated in certain populations. Specifically, live vaccines should not be given during pregnancy, and they are contraindicated in persons with known severe immunodeficiency (for example, from hematologic or solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long‑term immunosuppressive therapy).

    Ervebo (rVSVΔG‑ZEBOV‑GP) has important limitations that must be communicated to recipients: the duration of protection is unknown, and Ervebo does not protect against other species of Ebolavirus or Marburgvirus. Effectiveness when given with antivirals, immune globulin, or blood/plasma transfusions is also unknown; counsel patients accordingly.

    The policy lists CPT code 90625 (cholera vaccine, live, adult dosage, oral) among procedure codes included in the CPB's coding table and identifies it as a code that is not covered for indications listed in this Clinical Policy Bulletin.

    Randomized trial data and systematic reviews indicate limited utility for some travelers' diarrhea vaccines. Evidence does not support routine use of vaccines such as Dukoral® (killed whole‑cell oral cholera vaccine with B subunit) or other ETEC‑specific vaccines for broad traveler protection; while some trials showed reduced ETEC diarrhea in select settings, overall preventive impact for general travelers is limited and must be balanced against cost and adverse effects.

    These sections do not include explicit statements labeling travel vaccines as 'not medically necessary' across the board. Rather, systematic review conclusions are presented—for example, the yellow fever vaccine safety review concluded it was not possible to affirm a higher risk of adverse events in immunocompromised individuals, reflecting uncertainty rather than a blanket non‑coverage determination.

    Billing Codes and Coding Guidance

    Covered CPT Codes (when selection criteria met)CPTCovered
    90589Chikungunya virus vaccine, live attenuated, for intramuscular use.
    90626Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular.
    90627Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use.
    90632Hepatitis A vaccine (HepA), adult dosage, for intramuscular use.
    90633Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use.
    90634Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use.
    90636Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use.
    90675Rabies vaccine, for intramuscular use.
    90676Rabies vaccine, for intradermal use.
    90690Typhoid vaccine, live, oral.
    1–10 of 33
    1/4
    CPT codes not covered for indications listed in the CPBCPTNot Covered
    90625Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use.
    HCPCS covered if selection criteria are metHCPCSCovered
    G0010Administration of hepatitis B vaccine.
    Other HCPCS related codesHCPCS
    G0310Immunization counseling by physician when vaccine not administered same date, 5-15 mins (Medicaid).
    G0311Immunization counseling when vaccine not administered same date, 16-30 mins (Medicaid).
    G0312Immunization counseling when vaccine not administered same date for ages under 21, 5-15 mins (Medicaid).
    G0313Immunization counseling when vaccine not administered same date for ages under 21, 16-30 mins (Medicaid).
    Other HCPCS related codesHCPCS
    G0310Immunization counseling by physician when vaccine not administered same date, 5-15 mins (Medicaid).
    G0311Immunization counseling when vaccine not administered same date, 16-30 mins (Medicaid).
    G0312Immunization counseling when vaccine not administered same date for ages under 21, 5-15 mins (Medicaid).
    G0313Immunization counseling when vaccine not administered same date for ages under 21, 16-30 mins (Medicaid).
    ICD-10 CodesICD-10
    Z23Encounter for immunization
    Referenced vaccines and regulatory notes (no explicit billing codes provided in this excerpt)mixed
    No codes listed
    Age and timing thresholds — selected examples
    Cholera (Vaxchora)Indicated for persons 2 through 64 years of age traveling to endemic areas (single-dose, live oral).
    Rabies (pre-exposure schedule)Pre-exposure dosing per policy: days 0, 7, and booster on day 21 or 28 (standard pre-exposure schedule).
    Yellow feverPrimary: single 0.5 mL subcutaneous dose given 10 days to 10 years before travel; booster: every 10 years.
    Typhoid (live, oral)Primary: 4 oral doses; re-immunize every 5 years (attenuated live bacteria formulation).
    Chikungunya (Ixchiq)Indicated for persons 18 years and older (single intramuscular dose); safety/effectiveness not established <18 years.

    Provider Actions, Documentation, and Authorization

    Documentation Required

    Provider Actions, Documentation, and Authorization

    None specified in this excerpt.

    • Providers should confirm member plan benefits and coverage for travel vaccines prior to administration; many Aetna HMO plans exclude travel vaccine coverage while some traditional plans cover medically necessary travel vaccines for members with preventive benefits.
    • Use appropriate CPT/HCPCS and ICD-10 codes when billing; report ICD-10 Z23 for encounters for immunization where applicable.
    • When criteria in the policy are met, use the listed CPT/HCPCS codes for vaccine administration and vaccine products.
    • Document clinical indication for travel-related vaccination (including destination/risk, medical history, contraindications such as pregnancy or severe immunodeficiency for live vaccines, and prior immunity/vaccination history e.g., measles) and any prior authorization or benefit-verification outcomes.
    • Prior authorization may be required for newly approved travel vaccines (e.g., chikungunya vaccine) or for specific products per the member’s plan; obtain and retain documentation supporting medical necessity if PA is required.
    • No step therapy rules are specified in this excerpt.

    Background and Context

    The Centers for Disease Control and Prevention (CDC) provides destination‑specific vaccine recommendations for travelers. Commonly considered travel vaccines referenced in the policy include yellow fever, typhoid, cholera, Japanese encephalitis, tick‑borne encephalitis, rabies, hepatitis A and B, meningococcal, measles/mumps/rubella, polio, and Zaire ebolavirus (Ervebo). Providers should consult CDC guidance and the member's benefit plan when determining indication and timing for travel immunizations.

    Definitions and Key Terms

    Experimental and investigational vaccines — definition & examples
    DefinitionVaccines for which clinical value has not been established or for which effective vaccines have not yet been developed (examples cited: malaria vaccine for travel; oral or skin‑patch cholera vaccines for prevention of ETEC diarrhea).
    Example — Malaria vaccinesMalaria vaccines for travel are considered experimental/investigational because an effective malaria vaccine has yet to be developed (Cochrane reviews cited).
    Example — Oral/skin‑patch cholera/ETEC vaccinesOral or skin‑patch cholera vaccines for prevention of entero‑toxigenic E. coli (ETEC) diarrhea are considered experimental/investigational because clinical value has not been established.
    Ixchiq (chikungunya vaccine) — key facts
    Product and formulationIxchiq (Valneva) — live, weakened chikungunya virus formulation administered as a single intramuscular injection.
    IndicationFDA-approved for prevention of chikungunya disease in individuals 18 years of age and older who are at increased risk of exposure (accelerated approval).
    Contraindications/precautionsContraindicated in immunocompromised individuals and in persons with a history of severe allergic reaction to any component; safety and effectiveness not established in persons <18 years.
    Safety noteVaccine viremia occurs in the first week after administration and resolves by 14 days; unknown whether vaccine virus can be vertically transmitted — weigh pregnancy risks vs wild‑type exposure.
    Ticovac (tick‑borne encephalitis vaccine) — key facts
    Product and approvalTicovac (Pfizer) — tick‑borne encephalitis (TBE) vaccine approved by FDA on August 13, 2021 for active immunization to prevent TBE in individuals 1 year of age and older.
    Efficacy/immunogenicityClinical trials showed pooled seropositivity rates of ~99–100% in 1–15 year olds and 94–99% in adults >15 years following three doses; real‑world effectiveness reported 96–99% after ≥2 doses.
    Safety/tolerabilityGenerally well tolerated across age groups; most common reactions: local tenderness, headache, local pain, fever, restlessness, fatigue, and muscle pain.
    Healthcare personnel (HCP) — definition
    DefinitionHealthcare personnel (HCP): all paid and unpaid persons serving in healthcare settings who have potential for direct or indirect exposure to patients or infectious materials (includes clinical and non‑clinical staff such as EMS, nurses, physicians, lab personnel, environmental services, administrative and volunteer staff).
    Scope examplesIncludes emergency medical service personnel, nursing assistants, technicians, clinical laboratory personnel, autopsy personnel, therapists, phlebotomists, pharmacists, students, trainees, contractual staff, and personnel not directly involved in patient care who could be exposed (clerical, dietary, environmental services, laundry, security, engineering, administrative, billing, volunteers).
    Context of useUsed to identify persons recommended for pre‑exposure Ervebo vaccination when at potential risk of Zaire ebolavirus exposure (e.g., outbreak responders, BSL‑4 laboratorians, HCP at designated Ebola Treatment Centers).

    Revision History

    2001-04-13effective_date

    Policy originally became effective.

    2019-12-19vaccine_approval_note

    FDA approved Ervebo (rVSVΔG-ZEBOV-GP) for prevention of Zaire ebolavirus disease in persons 18 years and older.

    2020-02-26acip_recommendation

    ACIP recommended pre-exposure vaccination with Ervebo for adults 18 years and older at potential risk of exposure to Zaire ebolavirus.

    2024-02-01policy_reviewLatest

    Policy last reviewed (routine review).